JOURNAL ARTICLE

FDA Approves Lerodalcibep, Third-Generation PCSK9 Inhibitor, to Treat Hypercholesterolemia, Including HeFH.

  • Published In: Patient Care (Online), 2025. P. N.PAG 1 of 3

  • Database: CINAHL Ultimate 2 of 3

  • Authored By: Halsey, Grace 3 of 3

Abstract

The FDA announced its approval of lerodalcibep-liga (Lerochol; LIB Therapeutics) as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). LIB Therapeutics expects the injectable therapy to reach the US market in spring 2026, according to a company statement.

Additional Information

  • Source:Patient Care (Online). 2025/12, pN.PAG
  • Document Type:Journal Article
  • Subject Area:Politics and Government
  • Publication Date:2025
  • ISSN:1939-1897
  • Accession Number:190361034

Looking to go deeper into this topic? Look for more articles on EBSCOhost.